Skip directly to site content Skip directly to page options Skip directly to A-Z link


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
															Search

		Submit


Tuberculosis (TB)


Facebook
        Twitter
        LinkedIn
        Syndicate





Reported Tuberculosis in the United States, 2020										Related Pages
					Return to Main Menu
Technical Notes
National Tuberculosis Surveillance System
Reporting areas (i.e., the 50 U.S. states, the District of Columbia (DC), New York City, Puerto Rico, and other U.S. jurisdictions in the Pacific Ocean and Caribbean Sea) provide information about tuberculosis (TB) cases to the Centers for Disease Control and Prevention’s (CDC’s) National TB Surveillance System (NTSS) by using a standard case report form, the Report of Verified Case of TB (RVCT). TB cases are verified according to the TB case definition for public health surveillance (Appendix A). TB cases are reported and counted according to the recommendations for reporting and counting TB cases (Appendix B).
TB Case Definition
The current TB surveillance case definition was adopted by the Council of State and Territorial Epidemiologists in 2009. TB cases are verified according to the following specified laboratory and clinical criteria (Appendix A).
Laboratory Criteria for Diagnosis
A TB case may be verified by the laboratory case definition with ≥1 of the following criteria: (1) isolation of *Mycobacterium tuberculosis* complex from a clinical specimen; ***or*** (2) demonstration of *M. tuberculosis* complex from a clinical specimen by nucleic acid amplification test (NAAT), ***or*** (3) demonstration of acid-fast bacilli (AFB) in a clinical specimen when a culture has not been or cannot be obtained or is falsely negative or contaminated.
Clinical Case Criteria
A TB case may be verified by the clinical case definition in the presence of ***all*** of the following clinical criteria: (1) a positive tuberculin skin test (TST) result or positive interferon-gamma release assay (IGRA) result for *M. tuberculosis* complex; ***and***(2) other signs and symptoms compatible with TB (e.g., abnormal chest radiograph, abnormal chest computerized tomography [CT] scan, or other chest imaging study or clinical evidence of current disease); ***and***(3) treatment with ≥2 anti-TB drugs; ***and***(4) a completed diagnostic evaluation.
Provider Diagnosis
Provider diagnosis is not a component of the case definition for TB as described in Appendix A. However, when cases of TB are diagnosed but do not meet either the clinical or laboratory case definition, reporting areas have the option of verifying TB cases on the basis of provider diagnosis as described in Appendix B. Through 2008, the RVCT did not collect information about IGRA results. If an IGRA was performed in lieu of a TST, the RVCT would have indicated that a TST was not performed. Thus, culture- and smear-negative cases without a TST that were diagnosed by a positive IGRA result before 2008 were considered to have been confirmed by provider diagnosis. Starting in 2009, positive results for an IGRA have been included as part of the clinical case definition for TB confirmation. Anergic patients with a clinical presentation consistent with TB but without laboratory evidence of *M. tuberculosis* complex would also be an example of provider diagnosis and one that has not changed over time.
TB Case Verification Criteria Calculation
The software for TB surveillance developed by CDC includes a calculated variable for TB case verification called “VERCRIT,” which was modified in 2009. The new variables, NAAT result, IGRA for *Mycobacterium tuberculosis* complex at diagnosis, and initial chest CT scan or other chest imaging study were added to the VERCRIT calculation.
VERCRIT is calculated by using the following criteria in hierarchical order (beginning with the most preferred method of verification):
positive culture,
positive NAAT,
positive AFB,
clinical case confirmation, or
provider diagnosisReporting and Counting of TB Cases
TB cases that are verified but not countable for morbidity statistics should still be reported to CDC as a measure of programmatic and case management burden. However, data for non-countable TB cases are not included in this report.
Immigrants, refugees, and foreign visitors examined after arriving in the United States and receiving a diagnosis of TB disease requiring TB treatment should be reported and counted by the locality of their residence at the time of diagnosis. Persons in the United States ≥90 consecutive days (inclusive of report date) who are medically evaluated or treated for TB while in the United States should be reported and counted by the locality where the diagnostic evaluation for TB began.
RVCT Variables
Data regarding demographic characteristics, clinical or laboratory diagnosis, initial treatment, and treatment outcomes are collected through 3 RVCT report forms:
**RVCT form** — used for all patients with a verified TB case.
**Initial Drug Susceptibility Report (Follow-Up Report 1)** — used for all patients who had a culture that was positive for *M. tuberculosis* complex.
**Case Completion Report (Follow-Up Report 2)** — used for all patients who were alive at diagnosis.The instructions for completing the RVCT forms and the definitions for all data items are available in CDC’s RVCT instruction manual.1
Tabulation and Presentation of TB Data
This report presents summary data for TB cases counted by reporting areas through the end of 2020. TB cases are tabulated by year in which a reporting area verified a TB case and included it in its official annual TB case count. Since 2004, the published report has reflected updated information about the numbers of confirmed TB cases for each year from 1993 onward. U.S. totals include data from the 50 states and DC.
Trend data are presented in Tables 1–18. Age-group tabulations are based on a person’s age during the month and year he/she was reported to the health department as having a presumptive TB case. State or metropolitan area tabulations are based on a person’s reported residence. Percentages and rates are calculated using nonrounded numbers.
Origin of Birth
CDC uses U.S. Census Bureau definitions2 for national origin, where persons are U.S.-born if they were entitled to U.S. citizenship at birth, i.e., they were born in the United States or a U.S. territory or elsewhere to at least one U.S. citizen parent (with certain minor exceptions). All other persons are categorized as non-U.S.–born.
Rates
Rates are expressed as the number of cases reported each calendar year per 100,000 persons. Population denominators used in calculating TB rates were based on official census and midyear postcensal estimates from the U.S. Census Bureau. In Table 1, Table 28, and Table 29, the U.S. total populations for 1990–1999 were taken from the Bridged-Race Intercensal Population Estimates for July 1, 1990–July 1, 1999;3 populations for 2000–2009 were taken from the U.S. Census Intercensal Estimates of the Resident Population for the United States, Regions, States, and Puerto Rico for April 1, 2000–July 1, 2010;4external icon and populations for 2010–2020 were taken from the U.S. Census Annual Estimates of the Resident Population for the United States, Regions, States, and Puerto Rico: April 1, 2010 to July 1, 2020.5external icon Beginning in 2004, nonrounded numbers were applied to calculate the annual percentage change in the TB case rate.
During 2003, two modifications were made to the RVCT form: (1) multiple race entries (≥2 races reported for a person) were allowed, and (2) the previous category of “Asian/Pacific Islander” was divided into “Asian” and “Native Hawaiian/Other Pacific Islander.” To calculate rates for Table 2 and Table 4, denominators for 1993–1999 were obtained from the U.S. Census Monthly Postcensal Resident Population, by single year of age, sex, race, and Hispanic origin.6external icon For 2000–2009, denominators for Table 2 were obtained from U.S. Census Intercensal Estimates of the Resident Population by Sex, Race, and Hispanic Origin for the United States: April 1, 2000–July 1, 2010,7external icon and denominators forTable 4 were obtained from Intercensal Estimates of the Resident Population by Single Year of Age and Sex for States and the United States: April 1, 2000–July 1, 2010.7external icon For 2010–2020, denominators for Table 2 were obtained from the U.S. Census Monthly National Population Estimates by Age, Sex, Race, Hispanic Origin, and Population Universe for the United States: April 1, 2010 to December 1, 2020,8external icon and denominators for Table 4 were obtained from U.S. Census Annual Estimates of the Resident Population by Single Year of Age and Sex for the United States: April 1, 2010 to July 1, 2020.8external icon Four new trend tables with case rates were created for the 2020 Annual TB Report using data from 1994 and onward. Tables 2B and 2C report the trends of race-ethnicity among U.S.-born persons (Table 2B) and non-U.S.–born persons (Table 2C). Tables 4B and 4C report trends for different age groups among U.S.-born persons (Table 4B) and non-U.S.–born persons (Table 4C). Denominators for these new tables were obtained from the U.S. Census Bureau’s MDAT tool.9external icon Percentages by birth decade were calculated using cases from each birth decade cohort (derived from birth year of patient) divided by overall number of cases for each year (Table 4D).
The population source for nativity is the Current Population Survey,10external icon which is used to calculate case rates for U.S.-born and non-U.S.–born persons with diagnosed TB. U.S.-born populations include persons born in the 50 states and DC, those born abroad to U.S. parents, and those born in U.S. territories. In Table 5, the populations for U.S.-born and non-U.S.–born persons for 1993 were obtained from Quarterly Estimates of the United States Foreign-Born and Native Resident Populations: April 1, 1990–July 1, 1999.11txt iconexternal icon Denominators for computing the 1994–2018 rates were based on extrapolations from the U.S. Census Current Population Survey through DataFerrett (U.S. Census Bureau, Washington, DC)12, and denominators for 2019 and 2020 were obtained from the U.S. Census Bureau’s MDAT tool.9external icon Denominators for computing 2020 rates in Table 20 were obtained from U.S. Census Monthly National Population Estimates by Age, Sex, Race, Hispanic Origin, and Population Universe for the United States: April 1, 2010 to December 1, 2020.8external icon
Rates by Country of Birth
To calculate U.S. TB rates by country of birth for Table 6B, the average annual number of cases by country of birth reported to NTSS during 2016–2020 were used in the numerator. U.S. population estimates by country of birth were used for the denominator and were obtained from the U.S. Census Bureau, American Community Survey (ACS) Public Use Microdata Sample data, 2015–2019, 5-year file.13external icon At the time of this report, the 2016–2020 data had not been published. In ACS, country of birth is self-reported, and persons born outside the United States are asked to report country of birth on the basis of current international boundaries. Population estimates of persons from countries with ≥10,000 persons living in the United States are coded as a country.14external icon
Mortality Data
The annual mortality rate is calculated as the number of deaths caused by TB in that year, divided by the estimated population for the year, multiplied by 100,000 (Table 1). The number of deaths was obtained from CDC’s National Center for Health Statistics, Multiple Cause of Death Files, 1999–2018,15 available from CDC’s WONDER online database. Data were compiled from the 57 vital statistics jurisdictions through the Vital Statistics Cooperative Program.16 Finalized 2020 TB-related death data were unavailable at the time of publication.
Completion of TB Therapy
Table 10, Table 51, and Table 52 present information on the completion of TB therapy (COT). Data collected by RVCT Follow-Up Report-2 forms regarding date and reason therapy was stopped (e.g., the patient completed therapy, or the patient died) were used to calculate COT percentages. Cases were stratified by the indicated length of therapy, based on American Thoracic Society, CDC, and Infectious Diseases Society of America treatment guidelines in effect during the period covered and the patient’s initial drug-susceptibility test results, age, and disease site.17
In Table 51, the first column lists the total number of cases reported during 2018. The remaining columns are grouped under 2 headings: therapy lasting ≤1 year indicated and therapy lasting >1 year indicated. To be counted in the data presented here, patients eligible to complete therapy in ≤1 year were alive at time of diagnosis and had to have initiated therapy with ≥1 drug. Eligible patients did not have rifampin resistance; did not die in ≤1 year after initiating therapy; did not move out of the country in ≤1 year after initiating therapy; and did not have meningeal TB, bone or joint TB, or TB of the central nervous system, regardless of age. Additionally, TB patients aged 0–14 years were ineligible to complete therapy in ≤1 year if they had disseminated disease (defined for this report as miliary TB, a positive TB blood culture, or a positive NAAT on a blood specimen). Patients with culture-negative disease, those with an unknown culture status, and those with culture-positive disease but unknown initial drug-susceptibility test results were included under the category of therapy of ≤1 year indicated.
For the group with an indicated length of therapy of ≤1 year, percentages are displayed for both COT in ≤1 year and for COT regardless of duration (i.e., duration of therapy ≤1 year or >1 year). For COT ≤1 year, the numerator included only those patients completing therapy in ≤366 days (based on the dates therapy was started and stopped). Patients with missing dates were classified as “treatment not completed” for this calculation.
COT percentages, regardless of duration, were calculated by dividing the number of patients reported as having completed therapy by the number of total eligible patients. Patients with an outcome other than completed therapy (i.e., moved, lost to follow-up, refused treatment, or other) were classified as “treatment not completed.” Patients with an unknown outcome were also classified as “treatment not completed.” For the group of indicated therapy length >1 year, only COT percentages regardless of duration are presented. Table 10 provides percentages for COT ≤1 year and for COT regardless of duration for the group with an indicated therapy of ≤1 year only.
TB Disease Site
Miliary disease should be reported as a pulmonary form of TB (Table 7 and Table 34). Beginning in 2009, miliary disease could not be classified as a TB disease site because it is a clinical or a radiologic finding and should be recorded under Initial Chest Radiograph, Initial Chest CT Scan, or Other Chest Imaging Study. During 1997–2008, miliary disease was classified as both an extrapulmonary and a pulmonary form of TB. In publications before 1997, miliary disease was classified as extrapulmonary TB, unless pulmonary disease was reported as the major disease site.
Reporting of HIV Status
Information about HIV status for persons with TB is displayed in Table 11 and Table 46 for those persons not dead at diagnosis. Table 11 also lists trend data for persons aged 25–44 years as well as those aged 45–64 years. Reporting completeness for HIV status was 95% of TB patients tested among persons aged 25–44 years and completeness were 92% among persons aged 45–64 years during 2020; however, this variable is still underreported across jurisdictions. Data regarding the HIV-infection status of persons reported with TB should be interpreted with caution because these data are not representative of all TB patients with HIV infection. TB patients who are tested anonymously for HIV might choose not to share their testing results with their health care provider. TB patients managed in the private sector can receive confidential HIV testing, but results might not be reported to the health department’s TB program. Additionally, certain factors can influence HIV testing among TB patients, including the extent to which testing is targeted or routinely offered to specific groups (e.g., males aged 25–44 years, injection-drug users, or persons experiencing homelessness) and the availability of and access to HIV testing services. These data might overrepresent or underrepresent the percentage of TB patients known to be HIV-infected in a reporting area.
Primary Occupation for the Past Year
Table 43 reflects the modified 2009 RVCT variable, “Primary Occupation Within the Past Year”, which replaces the “Occupation Within Past 24 Months of TB Diagnosis” in previous reports. After the 2009 RVCT revision, “Multiple Occupation” was removed, and the “Retired” and the “Not Seeking Employment” categories were added.
Reason Therapy Was Stopped
Beginning in 2009, Table 12 and Table 49 include a patient’s adverse reaction to anti-TB drug therapy as an option for the reason therapy was stopped. The 2009 RVCT revision removed the option of “Moved” as a valid response to the variable Reason Therapy Stopped, and this option is therefore not reported after 2009. Those cases entered as “Moved” as reason therapy was stopped after 2009 are now categorized as “Unknown.”
Metropolitan Statistical Areas
Tables 53,54, 55 and 56 present data by metropolitan statistical areas (MSAs) having an estimated 2020 population of ≥500,000 persons. MSAs are defined by the White House Office of Management and Budget (OMB), and the definitions are based on the application of the 2010 OMB standards for delineating MSAs to U.S. Census Bureau population estimates.18external icon
The MSA definitions apply to all areas except the six New England states; those states are referred to collectively as the New England County Metropolitan Areas (NECMAs). MSAs are named for a central city in the MSA or NECMA, can include multiple cities and counties, and can cross state boundaries. For example, the TB cases and case rates presented for DC in Table 28 include only persons residing within DC’s geographic boundaries. However, the TB cases and case rates for the Washington, DC-MSA (Table 53) include persons residing within the multiple counties in the metropolitan area, including counties in Maryland, Virginia, and West Virginia. Cities or MSAs with incomplete or unavailable data were not included in the tables, and certain cities’ or MSAs’ total numbers might be underreported because of missing information.
National Tuberculosis Genotyping Service
The National Tuberculosis Genotyping Service conducts genotyping using two methods: spacer oligonucleotide typing (spoligotyping) and mycobacterial interspersed repetitive units–variable number of tandem repeats (MIRU–VNTR). All isolates are prepared for long-term storage by the service.
Genotype Clustering
A genotype cluster comprises ≥2 cases in a jurisdiction during a specified period that have *M. tuberculosis* complex isolates with matching genotypes. The jurisdiction and period can vary on the basis of the specific application. Cases that are part of the same genotype cluster are likely to be related by TB transmission in some way; however, the cases might not be directly related (i.e., one person did not necessarily transmit *M. tuberculosis* to another person in the cluster) or recently related (i.e., both persons might have contracted TB from the same person, but the exposure might have happened years ago). In TB GIMS, a cluster is defined as ≥2 cases with matching genotypes (spoligotype and 24-locus MIRU-VNTR) in a single county within a 3-year period.
*Mycobacterium bovis*
For culture-confirmed TB cases that have been genotyped, *Mycobacterium bovis*can be defined primarily on the basis of spoligotyping results. The genotype-based definition for *M. bovis*  requires either (1) the absence of spoligotyping spacers 3, 9, 16, and 39–43; the presence of ≥1 of the spacers 29–32; and the presence of ≥1 of the spacers 33–36; (2) the absence of spacers 3, 9, 16, and 39–43 and ≥2 copies of the repeated sequence at MIRU-VNTR locus 24 (i.e., loci 2687);19external icon or (3) determination based on microbiologic expertise. Data reported for 2004–2020 in Table 18 exclude cases of bacillus Calmette-Guérin *M. bovis*, which were defined as spoligotype 676773777777600 with x, y, or z in the second MIRU-VNTR position.
Recent Transmission
Estimates of recent transmission are based on a plausible source-case method that is described in detail elsewhere.20external icon Briefly, a given case is designated as attributed to recent transmission if a plausible source case with the following five characteristics can be identified in the national surveillance data: the same *M. tuberculosis*genotype, an infectious form of TB disease, patient’s residential location ≤10 miles of the given case, patient’s age ≥10 years, and a plausible source case ≤2 years before the given case. These criteria were field-validated using local epidemiologic assessments of whether 1,188 cases in three states were likely caused by recent transmission that was attributed to source cases reported during 1996–2000. Any given case with a plausible source case identified is included regardless of cluster size.
A TB case is designated as attributed to extensive recent transmission when the five criteria specified for recent transmission are met. Furthermore, the case belongs to a plausible transmission chain of at least six cases (i.e., the plausible source case and at least four other cases identified ≤3 years before the case being assessed, for a total of at least six cases).
These methods for estimating recent transmission can only be applied to culture-confirmed, genotyped cases that are eligible to be evaluated for recent transmission. Pediatric and other clinically diagnosed cases are likely underrepresented because cases without genotyping results are excluded. This limitation is especially relevant for TB cases in young children, which are most likely to be caused by recent transmission.
The percentages of cases attributed to recent transmission typically are higher in areas with fewer *M. tuberculosis*  genotypes and where prevalent or common genotypes have been predominant for years; among relatively closed populations and remote areas (e.g., parts of Alaska) recent transmission might be overestimated. As evidenced by whole-genome sequencing, genomic diversity might be greater than what is apparent using current genotyping methods among cases reported by areas bordering Mexico. Consequently, definitively distinguishing cases attributed to recent transmission from cases caused by reactivation of longstanding, untreated latent TB infection can be difficult using the methods reported here.ReferencesCenters for Disease Control and Prevention (CDC). Appendix B: Recommendations for Reporting and Counting Tuberculosis Cases (Revised May 13, 2009). In: *Report of Verified Case of Tuberculosis (RVCT) Instruction Manual pdf icon[3.8 MB].* Atlanta, GA: U.S. Department of Health and Human Services, CDC; June 2009.
US Bureau of Labor Statistics. https://www.bls.gov/cps/definitions.htm#foreignbornexternal icon [Internet]. Labor Force Statistics from the Current Population Survey: Concepts and Definitions. Washington, DC: U.S. Bureau of Labor Statistics; c2021 [cited 2021 Jan 27]. Available from: www.bls.gov/CPS
Centers for Disease Control and Prevention (CDC). *Documentation for Bridged-Race 1990–1999 Intercensal Population Estimates (Single-Year of Age Detail) for Calculating Vital Rates*. https://www.cdc.gov/nchs/nvss/bridged_race/data_documentation.htm
US Census Bureau. State intercensal tables: 2000–2010. Washington, DC: U.S. Census Bureau; 2016. https://www.census.gov/data/tables/time-series/demo/popest/intercensal-2000-2010-state.htmlexternal icon.
US Census Bureau. National Population Totals: 2010-2020. Washington, DC: U.S. Census Bureau; 2020. https://www.census.gov/programs-surveys/popest/technical-documentation/research/evaluation-estimates/2020-evaluation-estimates/2010s-totals-national.htmlexternal icon.
US Census Bureau. 1990s: national population datasets. Washington, DC: U.S. Census Bureau; 2016. https://www.census.gov/data/datasets/time-series/demo/popest/1990s-national.htmlexternal icon.
US Census Bureau. State intercensal datasets: 2000–2010. Washington, DC; 2018. https://www.census.gov/data/datasets/time-series/demo/popest/intercensal-2000-2010-state.htmlexternal icon.
US Census Bureau. National Population by Characteristics: 2010-2020. Washington, DC: U.S. Census Bureau; 2020. https://www.census.gov/programs-surveys/popest/technical-documentation/research/evaluation-estimates/2020-evaluation-estimates/2010s-national-detail.htmlexternal icon.
U.S. Census Bureau: Data.census.gov. Washington, DC. U.S. Census Bureau. https://data.census.gov/mdat/#/external icon
US Census Bureau. Current Population Survey. Washington, DC: U.S. Census Bureau; [undated]. https://www.census.gov/programs-surveys/cps.htmlexternal icon
US Census Bureau. Quarterly estimates of the United States foreign-born and native resident populations: April 1, 1990 to July 1, 1999. Washington, DC: U.S. Census Bureau; 2000. https://www2.census.gov/programs-surveys/popest/tables/1990-2000/national/totals/nat-nativity-sum.txttxt iconexternal icon.
US Census Bureau. The DataWeb: DataFerrett. Washington, DC: U.S. Census Bureau; [undated]. DataFerrett has been discontinued and has been replaced by https://data.census.gov/mdatexternal icon.
US Census Bureau. American Community Survey (ACS): Accessing PUMS data. Washington, DC: U.S. Census Bureau. https://www.census.gov/programs-surveys/acs/microdata/access.htmlexternal icon.
US Census Bureau. Public use microdata sample (PUMS) documentation. Washington, DC: U.S. Census Bureau; 2019. https://www.census.gov/programs-surveys/acs/data/pums.htmlexternal icon.
Centers for Disease Control and Prevention (CDC) National Center for Health Statistics, Multiple Cause of Death Files, 1999–2018. Atlanta, GA: U.S. Department of Health and Human Services, CDC; [undated]. https://wonder.cdc.gov/mcd.html
Centers for Disease Control and Prevention (CDC) Vital Statistics Cooperative Program (VSCP). Atlanta, GA: U.S. Department of Health and Human Services, CDC; [undated]. https://www.cdc.gov/nchs/vscp/confirmation.htm
Centers for Disease Control and Prevention. Treatment of tuberculosis, American Thoracic Society, CDC, and the Infectious Diseases Society of America. *MMWR Morb Mortal Wkly Rep.* 2003;52(No. RR-11):1-77. https://www.cdc.gov/mmwr/preview/mmwrhtml/rr5211a1.htm
US Census Bureau. Geographies: delineation files. Washington, DC: U.S. Census Bureau; 2018. https://www.census.gov/geographies/reference-files/time-series/demo/metro-micro/delineation-files.htmlexternal icon.
Scott C, Cavanaugh JS, Pratt R, Silk BJ, LoBue P, Moonan PK. Human Tuberculosis Caused by *Mycobacterium bovis* in the United States, 2006–2013. *Clinical Infectious Diseases*. 2016;63(5):594–601 https://academic.oup.com/cid/article/63/5/594/2237779external icon
France AM, Grant J, Kammerer JS, Navin TR. A field-validated approach using surveillance and genotyping data to estimate tuberculosis attributable to recent transmission in the United States. *Am J Epidemiol*. 2015; 182:799-807. https://academic.oup.com/aje/article/182/9/799/96259external icon
							
					
						Page last reviewed:  October 25, 2021					Content source: 	Division of Tuberculosis Elimination, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention homeTuberculosisBasic TB Factsplus iconHow TB SpreadsLatent TB Infection and TB DiseaseSigns & SymptomsTB Risk FactorsExposure to TBTB PreventionVaccinesTB & HIV CoinfectionTB and DiabetesTB TermsPersonal StoriesTesting & Diagnosisplus iconWho Should be TestedTesting for TB InfectionTesting in BCG-Vaccinated PersonsTB Screening and Testing of Health Care PersonnelTesting During PregnancyDiagnosing latent TB infection and TB diseaseTreatmentplus iconDeciding When to Treat Latent TB InfectionTreatment Regimens for Latent TB Infection (LTBI)Treatment for TB DiseaseAdverse EventsTB Treatment of Persons Living with HIVTB Treatment and PregnancyTB Treatment for ChildrenFrequently Asked QuestionsDrug-Resistant TBResearchplus iconTB Epidemiologic Studies Consortiumplus iconResearch ProjectsPublicationsTB Trials Consortiumplus iconStudy DescriptionsBackgroundBehavioral & Social Science ResearchHealth Care Settingsplus iconTB Infection Control in Health Care SettingsResources for TB Screening and Testing of Health Care Personnelplus iconFrequently Asked QuestionsTB in Specific Populationsplus iconHealth DisparitiesAsian PersonsBlack or African American PersonsHispanic or Latino PersonsChildrenPregnancyCorrectional FacilitiesPeople Experiencing HomelessnessInternational TravelersLaboratory Informationplus iconDrug Susceptibility TestingFalse-Positive Investigation ToolkitInterim Laboratory Biosafety Guidance for XDR  tuberculosis strainsModel Performance Evaluation Program (MPEP)Rapid Molecular Testing to Detect Drug-Resistant TB in the USplus iconExecutive SummaryIntroductionBackground on Tests for Molecular Detection of DRGeneral Considerations and Principles for a Molecular DR Testing ServicePossible Scenarios and Scope of Testing for a Molecular DR Testing ServiceResearch NeedsGeneral Recommendations of the Expert PanelCommunication Plan for the ReportRecommendationsReferencesPanel Members and CDC ParticipantsAppendix 1Appendix 2Appendix 3The Uses of Nucleic Acid Amplification Tests for the Diagnosis of TBplus iconGeneral ConsiderationsGeneral Recommendations of the Expert PanelRecommendations to ACET, CDC, DTBEData & Statisticsplus iconTB Incidence in the United StatesReported TB in the US, 2022 Surveillance Reportplus iconNational DataReporting Area DataRisk FactorsDemographicsTB Treatment and Case OutcomesDrug-Resistant TBMolecular SurveillanceTuberculosis in the United States, 2022 (Slide Set)Archived Surveillance Reports and Slide Sets2021 State and City ReportArchived State and City ReportsProfessional Resources & Toolsplus iconTools for Healthcare ProvidersResources for TB Programsplus iconStrengthening Civil Surgeons’ Capacity to Improve LTBI Surveillance and Outcomes Among Status AdjustersNotice of Funding Opportunity (NOFO)Program EvaluationTB Centers of ExcellenceTB Elimination AllianceTB Genotypingplus iconConventional TB GenotypingWhole Genome SequencingTB GIMSAnalytic ToolsLatent Tuberculosis Infection ResourcesPublications & Productsplus iconPatient and Public MaterialsFact SheetsGuidelinesplus iconControl & EliminationDrug-Resistant TBInfection Control & PreventionLaboratory & GenotypingTB & HIVTB in Specific PopulationsTesting & DiagnosisTreatmentVaccines & ImmunizationsArchived TB GuidelinesGuides & Toolkitsplus iconAggregate ReportsCDC TB Surveillance TrainingCore CurriculumEffective TB Interviewing for Contact InvestigationEthnographic GuidesFalse-Positive Investigation ToolkitForging Partnerships to Eliminate TuberculosisGuide to Application of GenotypingLTBI: A Guide for Primary Health Care ProvidersMantoux Tuberculin Skin Testing ProductsReport of Verified Case of Tuberculosis (RVCT)Self-Study ModulesTB Contact Investigation Interviewing Skills CourseTB eDOT ToolkitUnderstanding the TB Cohort Review ProcessNewslettersplus iconTB Notes, No. 4, 2023TB Notes, No. 3, 2023TB Notes. No. 2, 2023TB Notes. No. 1, 2023TB Notes, No. 4, 2022TB Notes, No. 3, 2022TB Notes, No. 2, 2022TB Notes, No. 1, 2022TB Notes, No. 4, 2021TB Notes, No. 3, 2021TB Notes, No. 2, 2021TB Notes, No. 1, 2021Pamphlets, Brochures, Bookletsplus iconQuestions and AnswersPatient Education SeriesTuberculosis - Get the FactsTuberculosis - The Connection between TB and HIV12-Dose Regimen for Latent TB Infection-Patient Education BrochurePostersplus iconMantoux Tuberculin Skin Test Wall ChartWorld TB DayThink TBStop TBTake on TBReports & Articlesplus iconDTBE Authored Journal ArticlesTuberculosis Laboratory Aggregate ReportsSlide Setsplus iconIntroduction to TuberculosisEpidemiology of Tuberculosis Among Non-U.S.​–Born Persons in the United States, 1993–2016Self-Study Modules on Tuberculosis, 1-5 Slide SetsThe Tuberculosis (TB) in Correctional Settingsplus iconFacilitator GuideIntroduction to TB GenotypingEpidemiology of Tuberculosis in Correctional Facilities, United States, 1993-2017Prevention and Control of Tuberculosis in Correctional and Detention FacilitiesGuidelines for Preventing the Transmission of M. TB in Health care SettingsInvestigation of Contacts of Persons with Infectious TBEpidemiology of Pediatric Tuberculosis in the United StatesTargeted Tuberculosis Testing and Treatment of Latent Tuberculosis InfectionElectronic Tools & ResourcesWeb-Based Courses & Webinarsplus iconTB 101 for Health Care WorkersContent SyndicationInfographicsplus iconSocial Media GraphicsCustomizable Take on TB Infographic with InstructionsEventsWorld TB Dayplus iconU.S. TB ChampionsHistoryFeaturesplus iconTB Risk FactorsTreating Latent TB Infection with Short-Course RegimensWorld Tuberculosis (TB) Day 2021World Tuberculosis (TB) Day 2020Linksplus iconState TB Control OfficesAbout Usplus iconMission Statement and Activitiesplus iconDTBE Strategic PlanNational TB Program ObjectivesOrganization ChartAdvisory Groupsplus iconFederal TB Task Force To receive email updates about this page, enter your email address: Email Address			What's this?				Submit


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue